Stephen Anesi, MD
Ophthalmology · Waltham, MANPI 1003052788
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $782,935 of the $921,614 with a category attached, or 85.0%. Mallinckrodt Hospital Products Inc. accounts for 66.9% of it on its own, with 38 other manufacturers making up the rest. Among ophthalmology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,155 payments — averaging $797.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$616K
- Mallinckrodt Enterprises LLC$119K
- Eyepoint US, Inc.$44K
- Bausch & Lomb Americas Inc.$35K
- AbbVie$32K
- Alimera Sciences, Inc.$29K
- plus $46K from 33 others
What the payments were for
- Consulting fees$62,4427%
- Speaking & faculty fees$782,93585%
- Travel & lodging$41,9035%
- Food & beverage$34,0924%
- Education$1960%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$726,927
- YUTIQ$71,087
- XIPERE$33,165
- Iluvien$27,921
- PURIFIED CORTROPHIN GEL$22,887
- Humira$16,876
- XEN GLAUCOMA TREATMENT SYSTEM$9,761
- TEPEZZA$3,150
- OMNI(R) SURGICAL SYSTEM (US)$1,891
- SION SURGICAL INSTRUMENT$424
- Implantable Miniature Telescope$334
- Clareon$308
- XDEMVY$293
- MIEBO$254
- XIIDRA$254
- OMNI$228
- Rocklatan$227
- Rhopressa$227
- TYRVAYA$223
- IHEEZO$185
How this compares
$921,614 in reported general payments places this provider in the 95th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 120 | $8,145,418 |
| Humira(Cf) PenAdalimumab | 148 | $1,285,683 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 64 | $570,954 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 16 | $450,436 |
| OxervateCenegermin-Bkbj | 15 | $423,298 |
| RemicadeInfliximab | 61 | $392,891 |
| CortrophinCorticotropin | 11 | $359,185 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $291,601 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 17 | $152,865 |
| RestasisCyclosporine | 106 | $128,906 |
| RituxanRituximab | 15 | $87,481 |
| ProlensaBromfenac Sodium | 94 | $65,627 |
| XiidraLifitegrast | 45 | $48,663 |
| CequaCyclosporine | 49 | $38,167 |
| Alphagan PBrimonidine Tartrate | 80 | $30,142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $616,327 | $8,145,418120 claims |
| Dompe US, Inc.Oxervate | $483 | $423,29815 claims |
| AbbVieRestasis, Alphagan P, Lumigan, Combigan | $32,247 | $203,092289 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Zirgan | $34,601 | $91,977114 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax, Loteprednol Etabonate | $462 | $80,677137 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $627 | $38,16749 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $543 | $20,72911 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $705 | $16,82226 claims |
| AlconSimbrinza | $1,340 | $13,16645 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 653 ophthalmology providers in Massachusetts.
Other ophthalmology in Waltham
- Peter ChangWaltham$992K
- Jonathan TalamoWaltham$225K
- Nandini VenkateswaranWaltham$149K
- Charles FosterWaltham$24K
- Rishi SinghBoston$1.7M
- David LallySpringfield$328K
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Mark LatinaReading$279K
- Dean EliottBoston$250K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.